Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
Nicholas C. Turner(Institute of Cancer Research), Massimo Cristofanilli(Cornell University), Sherene Loi(The University of Melbourne), Nadia Harbeck(Breast Center), Cynthia Huang Bartlett(Pfizer (United States)), María Koehler(Pfizer (United States)), Sophia Randolph(Pfizer (United States)), C. Giorgetti(Kyiv City Clinical Oncology Center), Sibylle Loibl(Goethe University Frankfurt), Ke Zhang(Pfizer (United States)), Sunil Verma(VA Boston Healthcare System), Fabrice André(Inserm), Jungsil Ro(Western University), Hiroji Iwata(Aichi Cancer Center)
Cited by 1,584
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k